New dosing schedules of dasatinib for CML and adverse event management

New dosing schedules of dasatinib for CML and adverse event management

<p>Abstract</p> <p>Resistance to imatinib in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has emerged as a significant clinical issue. Dasatinib is a tyrosine kinase inhibitor that has 325-fold greater i...

Full description

Bibliographic Details
Main Author:	Wong Siu-Fun
Format:	Article
Language:	English
Published:	BMC 2009-02-01
Series:	Journal of Hematology & Oncology
Online Access:	http://www.jhoonline.org/content/2/1/10

Similar Items

An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis
by: Burak Uz, et al.
Published: (2016-01-01)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
by: Yang Allen S, et al.
Published: (2009-11-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
by: Monika Conchon, et al.
Published: (2011-01-01)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
by: E.V. Morozova, et al.
Published: (2015-12-01)

COVID-19 Induced Pancytopenia in a Major Molecular Response CML patient on Dasatinib: A Case Report and Review of Literature
by: Balraj Singh, et al.
Published: (2021-01-01)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
by: E.V. Morozova, et al.
Published: (2015-01-01)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
by: Mariana Serpa, et al.
Published: (2010-01-01)

Personalised genetic management of CML
by: Alikian, Mary
Published: (2016)

Pharmacokinetics of Dasatinib
by: Jana Hořínková, et al.
Published: (2019-10-01)

The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology
by: Gisele P. Oliveira, et al.
Published: (2015-07-01)

The new European leukemianet recommendations for treating CML
by: Rüdiger Hehlmann
Published: (2020-10-01)

The role of dasatinib in the management of chronic myeloid leukemia
by: Chen R, et al.
Published: (2015-02-01)

Resistant Bilateral Chylous Effusion as a Late Adverse Effect of Dasatinib Treatment in Chronic Myeloid Leukaemia
by: Emine Zengin, et al.
Published: (2019-08-01)

CML: Evolution and design
by: Murray-Rust Peter, et al.
Published: (2011-10-01)

Optimisation of CML therapy
by: Neelakantan, Pratap
Published: (2014)

Adverse event management
by: Aline Gonzalez Vigani

Haemorrhagic Colitis Caused by Dasatinib
by: Nishant Patodi, et al.
Published: (2012-01-01)

DASATINIB IN CHRONIC MYELOID LEUKEMIA
by: Mojca Modic
Published: (2008-04-01)

Studies on the Chloramphenicol Halogenase CmlS
by: LATIMER, RYAN
Published: (2010)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
by: Shu-Ping Lee, et al.
Published: (2019-04-01)

Pharmacological control of CAR T-cells by dasatinib
by: Mestermann, Katrin
Published: (2020)

MANAGEMENT OF ADVERSE EVENTS IN THE HOSPITAL
by: Danguolė Jankauskienė, et al.
Published: (2019-12-01)

Characterization of the function of Calmodulin-like (CML) 23 and CML24 in the Arabidopsis thaliana circadian clock
by: Mohd Noh, Nur Izzati
Published: (2015)

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
by: Rhodora C. Calizo, et al.
Published: (2019-05-01)

Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
by: Araujo JC, et al.
Published: (2013-03-01)

Predictors of long term adverse events after scheduled endovascular coronary interventions
by: E. O. Vershinina, et al.
Published: (2018-08-01)

CMLLite: a design philosophy for CML
by: Townsend Joe A, et al.
Published: (2011-10-01)

CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
by: Lodovico Balducci
Published: (2014-05-01)

Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01)

Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009-03-01)

Systematic review of dasatinib in chronic myeloid leukemia
by: Breccia M, et al.
Published: (2013-03-01)

Dasatinib: ten years of clinical practice worldwide
by: K. M. Abdulkadyrov, et al.
Published: (2016-03-01)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
by: Franck Rahaghi, et al.
Published: (2021-03-01)

A New Image Encryption Algorithm Based on CML and DNA Sequence
by: Xingyuan Wang, et al.
Published: (2018-01-01)

Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01)

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency
by: Kelly Airiau, et al.
Published: (2018-06-01)

The importance of comorbidity and the usefulness of therapeutic early shift in the management of CML patients
by: Fabio Stagno
Published: (2015-10-01)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)